Utah Allows Nolla Health’s AI to Prescribe Acne Treatments Without Prior Doctor Review

An AI-generated acne prescription will no longer always need a doctor’s approval before reaching a Utah pharmacy. Nolla Health is starting a state-authorized pilot on October 5, 2026, that removes that checkpoint after an initial physician-review phase, Bloomberg reports. The exception covers topical acne treatments—not unrestricted AI medical practice.

From a face scan to a pharmacy

Patients begin by scanning their face in Nolla’s app and entering their medical history and personal information. The software analyzes their skin, assesses oiliness and assigns an acne severity score ranging from clear skin to severe acne. It combines that score with the patient’s medical information to recommend a medication.

The choice is restricted to eight approved treatments applied to the skin. Pills and hormone therapies are excluded. CEO Luis Wenus describes the medications as low-risk; Nolla’s team says their adverse effects are limited to localized irritation or dryness. That safety assessment is the company’s, not a finding from the pilot.

Doctors move from approval to auditing

Utah’s Office of Artificial Intelligence Policy authorized a narrow waiver of the state requirement that a prescriber be a licensed physician. Wenus said prescriptions will still carry a clinician’s name even when no human professional writes them. Human oversight remains, but its timing and coverage change in three successive stages.

Nolla engaged with the Utah Medical Licensing Board before authorization. Those discussions led to a third-party physician appointed by the board overseeing prescription reviews. The pilot lasts one year, with renewal for two more years possible at the AI policy office’s discretion.

A cheaper service, with responsibility written into the contract

Wenus puts the app’s price at about $5 a month, with compounded medications available at about $50 a month. Nolla argues that remote, automated care can reduce waiting and travel while leaving providers more time for skin cancer and complex inflammatory diseases. Those are the company’s promised benefits.

The regulatory safeguards address responsibility as well as review. Office director Zachary Boyd said the program requires malpractice insurance covering AI-generated prescriptions. Nolla’s contract also includes special duty-of-care provisions defining its responsibilities to patients, intended to help courts handle cases involving an AI-issued prescription.

Board involvement follows friction over Utah’s earlier Doctronic pilot for AI-approved prescription refills. The medical board said it had not been consulted and warned of risks to residents. The AI policy office subsequently removed two medications after consultation. Nolla’s narrower drug list and advance board engagement distinguish this authorization from that dispute.